1COV Fundamental Analysis - COVESTRO AG

Fundamental Rating

Overall 1COV gets a fundamental rating of 2 out of 10. We evaluated 1COV against 66 industry peers in the Chemicals industry. 1COV may be in some trouble as it scores bad on both profitability and health. 1COV has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 1COV has reported negative net income.

In the past year 1COV had a positive cash flow from operations.

In multiple years 1COV reported negative net income over the last 5 years.

1COV had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -2.86%, 1COV is doing worse than 69.70% of the companies in the same industry.

1COV has a Return On Equity of -6.14%. This is in the lower half of the industry: 1COV underperforms 71.21% of its industry peers.

		Industry Rank	Sector Rank
ROA	-2.86%
ROE	-6.14%
ROIC	N/A

ROA(3y)-1.76%

ROA(5y)1.73%

ROE(3y)-3.61%

ROE(5y)3.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

1COV's Operating Margin has declined in the last couple of years.

1COV has a worse Gross Margin (14.09%) than 77.27% of its industry peers.

In the last couple of years the Gross Margin of 1COV has declined.

1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	14.09%

OM growth 3Y-78.51%

OM growth 5Y-54.06%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-18%

GM growth 5Y-7.1%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.

1COV has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, 1COV has more shares outstanding

The debt/assets ratio for 1COV has been reduced compared to a year ago.

2.2 Solvency

1COV has an Altman-Z score of 2.35. This is not the best score and indicates that 1COV is in the grey zone with still only limited risk for bankruptcy at the moment.

With a Altman-Z score value of 2.35, 1COV perfoms like the industry average, outperforming 54.55% of the companies in the same industry.

1COV has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.

1COV's Debt to Equity ratio of 0.34 is fine compared to the rest of the industry. 1COV outperforms 62.12% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.34
Debt/FCF	N/A
Altman-Z	2.35

ROIC/WACCN/A

WACC6.4%

2.3 Liquidity

A Current Ratio of 1.39 indicates that 1COV should not have too much problems paying its short term obligations.

1COV's Current ratio of 1.39 is on the low side compared to the rest of the industry. 1COV is outperformed by 68.18% of its industry peers.

1COV has a Quick Ratio of 1.39. This is a bad value and indicates that 1COV is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.74, 1COV is not doing good in the industry: 80.30% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.39
Quick Ratio	0.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

1COV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.54%.

The Revenue has decreased by -1.98% in the past year.

Measured over the past years, 1COV shows a small growth in Revenue. The Revenue has been growing by 2.70% on average per year.

EPS 1Y (TTM)-17.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.42%

Revenue 1Y (TTM)-1.98%

Revenue growth 3Y-3.75%

Revenue growth 5Y2.7%

Sales Q2Q%-8.43%

3.2 Future

1COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.27% yearly.

1COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.72% yearly.

EPS Next Y-7.01%

EPS Next 2Y60.31%

EPS Next 3Y48.4%

EPS Next 5Y20.27%

Revenue Next Year-6.95%

Revenue Next 2Y-1.93%

Revenue Next 3Y-0.15%

Revenue Next 5Y0.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

1COV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

The Price/Forward Earnings ratio is 74.14, which means the current valuation is very expensive for 1COV.

Compared to the rest of the industry, the Price/Forward Earnings ratio of 1COV indicates a slightly more expensive valuation: 1COV is more expensive than 68.18% of the companies listed in the same industry.

1COV is valuated expensively when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	74.14

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1COV indicates a slightly more expensive valuation: 1COV is more expensive than 66.67% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	16.26

4.3 Compensation for Growth

1COV's earnings are expected to grow with 48.40% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y60.31%

EPS Next 3Y48.4%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for 1COV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

COVESTRO AG

FRA:1COV (10/23/2025, 5:21:56 PM)

-0.2 (-0.33%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)07-31 2025-07-31/bmo

Earnings (Next)10-30 2025-10-30

Inst Owners25.07%

Inst Owner ChangeN/A

Ins Owners0.03%

Ins Owner ChangeN/A

Market Cap11.34B

Revenue(TTM)13.84B

Net Income(TTM)-378000000

Analysts49.47

Price Target61.98 (3.3%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0.01

Dividend Growth(5Y)-70.61%

DP-0.26%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-681.03%

Min EPS beat(2)-1222.75%

Max EPS beat(2)-139.31%

EPS beat(4)1

Avg EPS beat(4)-330.2%

Min EPS beat(4)-1222.75%

Max EPS beat(4)201.01%

EPS beat(8)1

Avg EPS beat(8)-4314.94%

EPS beat(12)2

Avg EPS beat(12)-2882.46%

EPS beat(16)4

Avg EPS beat(16)-2161.83%

Revenue beat(2)0

Avg Revenue beat(2)-5.71%

Min Revenue beat(2)-6.91%

Max Revenue beat(2)-4.5%

Revenue beat(4)0

Avg Revenue beat(4)-5.8%

Min Revenue beat(4)-6.91%

Max Revenue beat(4)-4.5%

Revenue beat(8)0

Avg Revenue beat(8)-4.99%

Revenue beat(12)1

Avg Revenue beat(12)-3.71%

Revenue beat(16)4

Avg Revenue beat(16)-2.08%

PT rev (1m)-0.16%

PT rev (3m)-1.51%

EPS NQ rev (1m)-18.93%

EPS NQ rev (3m)-218.18%

EPS NY rev (1m)-31.72%

EPS NY rev (3m)-577.27%

Revenue NQ rev (1m)-4.92%

Revenue NQ rev (3m)-11.02%

Revenue NY rev (1m)-2.77%

Revenue NY rev (3m)-8.89%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	74.14
P/S	0.82
P/FCF	N/A
P/OCF	14.96
P/B	1.84
P/tB	2.26
EV/EBITDA	16.26

EPS(TTM)-2.01

EYN/A

EPS(NY)0.81

Fwd EY1.35%

FCF(TTM)-0.61

FCFYN/A

OCF(TTM)4.01

OCFY6.68%

SpS73.2

BVpS32.56

TBVpS26.55

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-2.86%
ROE	-6.14%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	14.09%
FCFM	N/A

ROA(3y)-1.76%

ROA(5y)1.73%

ROE(3y)-3.61%

ROE(5y)3.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)1.42%

ROCE(5y)6.03%

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-78.51%

OM growth 5Y-54.06%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-18%

GM growth 5Y-7.1%

F-Score4

Asset Turnover1.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.34
Debt/FCF	N/A
Debt/EBITDA	2.39
Cap/Depr	88.46%
Cap/Sales	6.32%
Interest Coverage	N/A
Cash Conversion	85.65%
Profit Quality	N/A
Current Ratio	1.39
Quick Ratio	0.74
Altman-Z	2.35

F-Score4

WACC6.4%

ROIC/WACCN/A

Cap/Depr(3y)75.52%

Cap/Depr(5y)82.02%

Cap/Sales(3y)5.15%

Cap/Sales(5y)5.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-17.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.42%

EPS Next Y-7.01%

EPS Next 2Y60.31%

EPS Next 3Y48.4%

EPS Next 5Y20.27%

Revenue 1Y (TTM)-1.98%

Revenue growth 3Y-3.75%

Revenue growth 5Y2.7%

Sales Q2Q%-8.43%

Revenue Next Year-6.95%

Revenue Next 2Y-1.93%

Revenue Next 3Y-0.15%

Revenue Next 5Y0.72%

EBIT growth 1Y-183.74%

EBIT growth 3Y-79.32%

EBIT growth 5Y-52.83%

EBIT Next Year267.68%

EBIT Next 3Y84.36%

EBIT Next 5Y41.79%

FCF growth 1Y-126.73%

FCF growth 3Y-60.36%

FCF growth 5Y-28.37%

OCF growth 1Y-37.61%

OCF growth 3Y-26.52%

OCF growth 5Y-8.84%

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens